MetaStat Focuses on Lead Product Opportunity and Bolstering Pipeline

Posted by Colleen Koski

April 19, 2013 at 9:13 AM

Yesterday, Crystal Research Associates published a 12-page Quarterly Update on MetaStat, Inc., a life sciences company developing next-generation diagnostic and therapeutic products for metastatic cancer. MetaStat is currently focused on three key initiatives within its pipeline: two diagnostic platforms (MetaSite™ Breast and MenaCalc™) as well as one therapeutic program (MenaBloc™). These candidates are overviewed on pages 5-8 of MetaStat's Quarterly Update.


Key Developments

Read More

Topics: MetaStat

AHRO Nears its Phase I Start with Appointment of Clinical Chair

Posted by Laura Swartz

April 11, 2013 at 11:13 AM

This morning, AtheroNova Inc. (AHRO-OTC) announced that it expanded its clinical expertise by adding Dr. Stephen Nicholls as Chair of the Company's Clinical Advisory Board. AtheroNova expects to launch its first Phase I clinical trial in the next few months for a drug called AHRO-001 to combat the accumulation of plaque in the arteries, thus the appointment of Dr. Nicholls--who has completed a postdoctoral fellowship in plaque imaging at the Cleveland Clinic and is the current heart disease Theme Leader at the South Australia Health and Medical Research Institute--is extremely well-timed. Dr. Nicholls will serve as a co-principal investigator in the upcoming clinical trial.

Read More

Topics: AtheroNova, AtheroNova

April 2013 Quarterly Update and Business Review on AtheroNova (AHRO)

Posted by Laura Swartz

April 5, 2013 at 3:08 PM

Read More

Topics: AtheroNova, AtheroNova

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic